Strategic Initiatives
12375 stories
·
45 followers

PART ONE: The way we run vaccine clinical trials is bizarre, unethical, and must change

1 Share

LLM (google/gemini-3.1-flash-lite) summary:

  • Standard Protocols: randomized placebo controlled trials represent the primary method for evaluating medical efficacy and identifying side effects.
  • Vaccine Methodology: vaccine clinical trials frequently deviate from standard drug testing by utilizing active comparators instead of inert placebos.
  • Active Comparator Issue: relying on other vaccines as control groups obscures the true incidence and severity of adverse reactions associated with the new product.
  • Trial Bias: the current testing design creates an incentive for approval by inflating the risk profile of control groups to minimize the appearance of vaccine related side effects.
  • Prophylactic Consideration: vaccine safety data requires increased rigor because these products are administered to healthy populations rather than individuals seeking treatment for acute illness.
  • Unblinding Justifications: claims that saline placebos cause functional unblinding in trials are rejected as insufficient, noting that other drug classes manage similar risks without substituting active controls.
  • Ethical Misconceptions: the argument that trial participants must receive an active treatment to maintain ethical standards contradicts the fundamental objective of conducting objective research for future patient benefit.
  • Regulatory Stagnation: proposed reforms to align vaccine approval standards with general medical regulations remain unimplemented despite advocacy from external reformers.

(Part 1: The trouble with vaccine trials)

Randomized placebo-controlled trials are the heart of medicine. They’re how doctors know new treatments work and have acceptable side effects compared to their benefits.

Except for vaccines. Vaccine trials often use a different, lower standard that makes it impossible to tell how serious their side effects are.

The loophole is especially bizarre because most vaccines are not given to sick people who need immediate help but prophylactically to healthy children.

Last year, Robert F. Kennedy Jr. and Food and Drug Administration reformers promised to make vaccines follow the same standards as other medicines. But, after loud and misleading pushback from reporters, health bureaucrats, and drug companies, the FDA didn’t.

Now the reformers have been run out of town. And kids and adults will continue to be pushed (or sometimes forced) to use vaccines approved without honest safety data.

(Honest explanations, no matter how painful they may be. The truths you won’t see anywhere else. Support this work, for pennies a day.)

So how does this loophole work?

Clinical trials typically split patients into two groups. One receives the new medicine being investigated. The other gets either an older treatment for the same disease or, if no older drug exists, a placebo, like a sugar pill or saline shot.

Because the patients are split at random before receiving the treatment, scientists can assume changes afterwards come from the treatment itself — not from some hidden difference between patients who take the drug and those who don’t.

That’s why clinical trials are as close to proof that a medicine has real benefit as we can get. (This is, of course, a major oversimplification about how clinical trials and drug development work. For more information, read this footnote.1)

But clinical trials don’t just measure benefits. All medicines have side effects. Trials let regulators, doctors, and patients see how a new drug’s risks compare to a placebo or older medicine.

But vaccine trials frequently have a crucial difference from those used for other medicines.

In vaccine trials, instead of testing new jabs against placebos, drug companies often use what they call “active comparators” — other vaccines.

To be clear, these are not situations where companies are testing new vaccines for diseases like measles, where older jabs for the same disease already exist. In those cases, it may be unethical to offer a true placebo arm.2

These are trials for entirely new vaccines treating diseases for which no approved treatment exists.3 In this case, the comparator is typically a vaccine for a different disease, one the trial is not testing.

(I said sugar pill, not Skittles!)

For example, in the pivotal 37,000-infant trial of PCV7, a vaccine against bacteria that can cause pneumonia and ear infections, infants and toddlers were given multiple shots of PCV7 or a vaccine against meningitis that itself wasn’t even approved at the time.

The effect of this sleight-of-hand is to make side effects for the vaccine being tested seem far more modest than they are, since the “active comparator” vaccine will have much worse side effects than a saline shot would.

Imagine a test that compared injuries from being hit by a sledgehammer to those from a baseball bat, instead of a sledgehammer and a styrofoam sledgehammer.

In turn, that deception fundamentally biases the trial to favor approval, since the FDA is of course supposed to consider side effect profiles when deciding on new products.

And side effects should be especially important in considering vaccine approval, since vaccines are usually given to healthy children or teens who often face a minimal risk of ever becoming gravely ill from the disease the shot is supposed to prevent.

(Another colorful graphic. So much science-y science! So many new pneumococcal vaccines. Too bad they forgot the placebos.)

In a 2014 paper in the journal Vaccine, a World Health Organization scientific working group wrote that “randomized, placebo-controlled trials are widely considered the gold standard for evaluating the safety and efficacy of a new vaccine.” (The WHO was considering whether placebo trials are acceptable even when a working vaccine already exists. It found that many times even in that case the answer was yes).

So why are vaccines different? Why are placebo-controlled trials not required in every instance?

Their advocates offer two primary justifications. Neither holds up.

The first is that vaccines have such intense side effects that using saline will tip people in the trial to whether they are getting the vaccine or the placebo — it will “functionally unblind” the trial and bias the outcomes.

But the same potential unblinding holds for non-vaccine medicines. Many antidepressants have sexual side effects, for example, but no one suggests that men in the placebo arms of antidepressant trials be given blood pressure medicines (which can cause impotence).

Ready to support Unreported Truths but not ready to subscribe? Try a one-time $5 donation (or more, if you like!)

Further, the fact that vaccines cause such serious side effects that the only possible way to keep a trial blinded is to use other vaccines in placebo arms is hardly a general argument for vaccine safety.

Finally, many vaccines are given to infants and toddlers — who will have no way of knowing they are in a clinical trial, much less realizing that the side effects they suffer are the result of a vaccine. In other words, the risk of functional unblinding should be lower, not higher, in trials for kids.

The second justification is that everyone participating in a vaccine trials “deserves” the benefit of some vaccine for participating. Last year, Dr. Steven Black, the lead investigator in the PCV7 trial, told PBS the trial had not been placebo controlled

due to the ethical concern of requiring the more than 15,000 control patients in the trial having to receive four doses of a placebo vaccine with no potential for benefit.

This is… not how clinical trials work. As Dr. Black should know.

The point of a clinical trial is not to benefit the people in it. Yes, they may benefit from getting a new treatment that other people haven’t received. But they may also be harmed, if the drug does not work or has severe side effects.

The point of running the trial is to test the medicine and find out. It is to gain information that will help future patients, not the ones in the trial.

This is one reason that researchers are strongly discouraged from enrolling prisoners or other people at risk of feeling coerced into joining clinical trials. Offering large payments is also unacceptable, though small ones for time and inconvenience are reasonable. (In very-early stage trials where a few healthy people face the risk of a compound never before tested in human beings, payments can be higher.)

In other words, potential trialists (or their parents, in the case of trials for children) should join trials freely, without hoping for any benefit other than the potential gain from a new drug — and the chance to altruistically help science and medicine.

This potential lack of benefit may seem wrong at first.

It’s not.

Not as long as no one is forced to participate in a trial, doctors clearly explain the potential risks and benefits to the people who enroll, and the people running the trial have a reasonable belief that the new drug will work and isn’t too risky.

We need clinical trials. Without them, all we have is guesswork.

And without true placebo arms, clinical trials are far less valuable, if not close to useless.

(Support work like this. Please.)

The key fact here, the one that vaccine advocates seem to forget: Vaccines are no different than other drug classes. They aren’t magic. Doctors, regulators, and most of all the people who receive them deserve clean and reliable information about them, including their side effects — just as they do with other drugs.

That’s what Dr. Vinay Prasad tried to say in November, when, as the chief medical officer of the FDA, he wrote in a memo that “vaccines will be treated like all other medication classes.”

And that’s what Robert F. Kennedy promised in April 2025, when he said the FDA would require placebo-controlled clinical trials for vaccines.

But Prasad is gone. And the FDA’s guidance on vaccines remains unchanged.

That’s not an accident.

(First of two parts. Coming soon: the misleading pushback from the media and health bureaucrats that derailed vaccine trial reform.)

1

In general, the development of new medicines progresses in three stages in humans.

In the first stage, a company gives a new compound to a few healthy volunteers to make sure it doesn’t unexpectedly kill anyone. In the second, which can cover anywhere from a few dozen to a few hundred people, the company figures out the best dose, the one that will have the most impact on the disease with the fewest side effects.

Then, in the third or pivotal stage, the company tests that dose in a large trial or trials, hoping to prove its medicine or vaccine will have a “statistically significant” impact on the disease.

The outcome being measured doesn’t necessarily have to be deaths or hospitalizations; an anti-migraine drug might be tested to see if it reduces the number of days each month a person has migraines. If the drug hits the goal the company has set in a way that is unlikely to be due to chance, the trial has succeeded and the drug is approvable — assuming its side effects are not too bad.

Even this length explanation deeply oversimplifies the drug development process and elides many crucial details. For example, a very large trial may be able to capture small differences between a drug and placebo, enabling a company to submit a drug for approval even if it may make little real world difference to patients. Or a company hoping to speed the process may begin the third, largest stage before finishing the second.

Further, in the case of diseases that are very rare or invariably fatal or both, regulators may accept less rigorous trial designs — a seemingly compassionate choice that has often led to later grief.

2

Even then the trial ethics are somewhat complex, because the effectiveness of new treatments can subtly decline over multiple generations of seemingly successful trials, ultimately leading to the introduction of new drugs that don’t work as well as older ones.

3

The mRNA Covid vaccine trials were a rare example of a trial for a novel vaccine run against true saline placebo. And not surprisingly, people who received the mRNA reported much severer side effects than those who given saline.

Read the whole story
bogorad
45 minutes ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete

Exclusive | Stripe in Talks to Buy Buzzy AI-Model Marketplace OpenRouter - WSJ

1 Share

LLM (google/gemini-3.5-flash-lite) summary:

  • Corporate Buyout Talks: stripe is reportedly negotiating to acquire openrouter in a massive capital-fueled tech merger.
  • Inflated Valuation: the speculative bubble could price the target startup at an absurd ten billion dollars.
  • Market Intermediary: openrouter operates a digital bazaar enabling corporations to consume various artificial intelligence models.
  • Capital Diversification: the potential acquirer seeks to hedge its bets and control spending away from dominant AI monopolies.
  • Expansion Strategy: the payments processor continues its aggressive push into artificial intelligence infrastructure and alternative assets.
  • Venture Backing: the startup previously secured funding from traditional venture capital funds and big tech parent companies.
  • Additional Takeover Bids: the same corporate buyers simultaneously pursued another multi-billion dollar acquisition deal for paypal.
  • Market Speculation: ongoing consolidation highlights the relentless pursuit of monopoly rents within the tech sector.

Alex Atallah speaking onstage at Pursuit's Annual Bash Gala, with a screen displaying his photo and title.OpenRouter CEO Alex Atallah, as he spoke in New York last year. Roy Rochlin/Getty Images

Stripe is in talks to acquire OpenRouter, a buzzy startup that helps developers choose between artificial-intelligence models, according to people familiar with the matter.

A transaction could be announced soon, though the talks could still fall apart or another suitor could emerge, the people said. The exact price being discussed couldn’t be learned, but some of the people said the business could fetch about $10 billion in a sale.

A number of other big tech companies had been considering potential deals for OpenRouter, the people familiar with the matter added.

OpenRouter is part of an emerging crop of startups that have found a lucrative niche between AI developers and the companies that want to use them. Founded in 2023, the company sells software that allows customers to easily access AI models built by OpenAI and Anthropic, as well as “open weight” alternatives that are free for anyone to download and run.

The company lists hundreds of large language models on its platform, allowing developers and businesses to easily access, compare and switch between them. 

A deal for OpenRouter could allow Stripe to seize upon a hot area of growth in the AI market. Many tech companies are looking to use a wide range of different AI models as a way to control spending and diversify away from OpenAI and Anthropic.

Stripe is primarily a payments processor, helping companies across the internet accept payments, but it has recently tried to expand into new areas such as infrastructure for AI and stablecoin payments. Its valuation hit $159 billion earlier this year. 

OpenRouter and Stripe also already have a partnership together, where OpenRouter uses Stripe to accept payments from its customers, among other things.

OpenRouter was most recently valued at $1.3 billion in May, according to PitchBook. Its backers include Menlo Ventures and CapitalG, the growth-venture fund of Google parent company Alphabet. The Information reported earlier that OpenRouter was fielding takeover interest.

Stripe has separately been pursuing a deal for PayPal alongside private-equity firm Advent International. The duo recently made an unsolicited offer that would value PayPal at roughly $53 billion.

For PayPal, however, that takeover price was seen as too low, according to people familiar with the matter. Stripe and Advent are still considering their next move with respect to PayPal, some of the people said.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Berber Jin covers startups and venture capital out of the Wall Street Journal's San Francisco office. His articles focus on the money and people powering Silicon Valley, with a recent focus on artificial intelligence. He previously covered the same topic for the Information, where he won a Best in Business award from the Society for Advancing Business Editing and Writing.

Berber is originally from Scarsdale, N.Y., and graduated from Stanford University.

Lauren Thomas is the lead reporter on M&A and shareholder activism for The Wall Street Journal in New York. She consistently breaks market-moving news about the biggest deals across all industries. Some of her scoops have included the $55 billion leveraged buyout of Electronic Arts, Union Pacific's more than $70 billion deal for Norfolk Southern, Exxon Mobil’s $60 billion deal for Pioneer Natural Resources, Google parent Alphabet's $32 billion deal for Wiz, Mars’s $30 billion deal for food maker Kellanova, and Sycamore's $10 billion take-private of Walgreens. She also frequently scoops the biggest proxy fights in corporate America, including recent battles at Starbucks, Disney and Southwest Airlines.

Before joining the Journal in October 2022, Lauren covered the retail and consumer industries at CNBC. There, she broke news on companies ranging from Target to Macy’s to Peloton, and she regularly appeared on CNBC TV programming.

A native of Spartanburg, S.C., Lauren graduated with high honors from the University of North Carolina at Chapel Hill, where she studied business journalism and Spanish.

Kate Clark covers startups, venture capital and artificial intelligence for The Wall Street Journal and is based in New York. Her reporting examines venture investment, private market dealmaking and the power dynamics between founders and investors in Silicon Valley and beyond. Previously, Kate was a senior reporter at Bloomberg News and a deputy bureau chief at The Information, where she led coverage of the venture capital and startup industry. She began her journalism career at TechCrunch and has won multiple Best in Business awards from the Society for Advancing Business Editing and Writing, including for breaking news coverage of OpenAI and for technology and markets reporting.

A Seattle native, she earned her degree from the University of Washington.


Up Next


Videos

Read the whole story
bogorad
3 days ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete

If You Want Abundance, You Have to Fix Permitting Law

1 Share
  • Bipartisan permitting problem: Housing, power, transmission, and other projects often take too long and cost too much, with NEPA serving as one part of a broader legal framework that can delay construction.
  • Limit unrelated exactions: Agencies should distinguish project-specific conditions from demands for broader public benefits, consolidating unrelated demands into a fee capped at a set share of construction costs.
  • Use objective standards: Permit requirements should be defined clearly in advance, with agencies identifying necessary studies, mitigation, and pollution controls before applicants invest in project design.
  • Keep permits focused: Agencies should evaluate the project actually proposed and rely on measurable emissions, safety, and capacity thresholds rather than speculative claims about cumulative or growth-inducing impacts.
  • Restrict environmental litigation: Enforcement lawsuits seeking to invalidate permits should generally be brought by federal or state attorneys general, while individuals alleging harm would retain remedies such as compensation, relocation, or project modifications.
  • Track agency performance: Permitting agencies should publish project dashboards showing application, completion, decision, litigation, construction, and cost milestones, and revise regulations when delays persist.
  • Preserve environmental standards: The proposed reforms are intended to improve objectivity, transparency, and accountability without weakening existing environmental requirements, allowing projects to proceed more predictably.



Democrats and Republicans now largely agree: the United States takes too long and pays too much to build housing, power plants, transmission lines, and everything else. Many within the “abundance” movement agree on the source of the problem: the National Environmental Policy Act, which requires federal agencies to study the environmental effects of major projects before approving them.

I have spent more than four decades helping clients obtain permits to build in California. The abundance movement’s central claim—that America has regulated itself out of the capacity to build—matches my experience in this work.

But NEPA is just one statute within a much larger legal framework governing permits. Stop with NEPA, and the same obstruction will simply flow through different channels. We can meet stringent environmental standards and still build quickly and efficiently, but only by making five fundamental changes to permitting law itself.

The law governing permits traces back to the Constitution’s prohibition on taking private property without just compensation. In the permitting context, courts have interpreted agency authority generously: an agency may demand fees, mitigation, or other exactions—concessions it requires from a developer as a condition of approval—provided that there is a “nexus” between the demand and the project, and that the exaction is roughly “proportionate” to what the developer seeks.

The two leading Supreme Court cases here are approaching their 40th birthdays—Nollan v. California Coastal Commission (1987) and Dolan v. City of Tigard (1994). Yet in the decades since, courts have established few practical limits to what satisfies the nexus-and-proportionality standard. As a result, an agency can withhold approval indefinitely until it gets what it wants.

Nor is this the only vague standard blocking development. If a developer gets past an agency, third-party opponents, whether NIMBY groups or special-interest advocates, can then sue to block the approved permit anyway. They simply must shift from the nexus-and-proportionality vocabulary of takings law to the impact-and-mitigation vocabulary of NEPA, the Clean Air Act, the Clean Water Act, and other environmental statutes, which in effect impose the same broad restrictions.

The first fix is to separate two kinds of demand that permitting law currently lets agencies blur together: conditions tied to the physical project itself and exactions that ask for something unrelated to it Those unrelated demands—“public benefit” exactions for off-site land conservation, community benefits, and the like—should be converted into a single fee, capped at a set share of construction costs (say, 3 percent) covering all public benefits collectively. Disputes over money then could not be used to halt an approved project.

Second, replace subjective standards with objective ones—both for what an application must contain and for what approval requires. Taxpayers face objective standards every April: each line of a tax form demands a factually correct answer. By contrast, the NEPA framework and most environmental permit criteria are rife with subjective, unknown, and often unknowable requirements that agencies themselves interpret inconsistently.

The result is an arbitrary regime. How much environmental impact study is enough? How much mitigation is enough? Litigants and judges reinterpret these standards with each case, establishing regulatory mandates from the bench without rulemaking or legislative authorization.

The practical consequences can be significant. Lawmakers may believe they have required a decision within one year, but an agency can simply decline to deem an application “complete” until two or more years of additional study are finished. If an agency’s application genuinely requires a two-year study, applicants should be on notice to complete it while designing the project—not to design the project, apply, and only then learn what’s missing.

Objective criteria don’t need to be lenient. The Clean Air Act and Clean Water Act effectively require the best available, feasible pollution controls. Agencies can specify the most recently approved control technology for each application type and offer a fast-track, 90-day pre-application review for applicants proposing something newer. That preserves “technology-forcing” standards inside an objective approval regime.

Third, confine the permit to the project that is actually proposed. Because permit law is only lightly bounded by the Constitution and dominated by subjective criteria, applicants seeking to build something new, or to modernize what exists, routinely receive a wish list from agency staff and stakeholders with requests well outside the project’s ambit.

These demands can include dedicating underutilized land to a nonprofit, shutting down an unrelated portion of a plant, or capping new sewer hookups for reasons of anti-growth politics rather than actual capacity. Such demands are often justified by loose concepts—“cumulative” and “growth-inducing” impacts—that have become formidable obstacles to timely agency action and inviting targets for policy-minded litigants and judges.

Fixing this does not require an agency to approve actually objectionable features of a project. If adding a pollution source to a factory would push the facility past a numerical emissions or toxic-risk threshold, the agency can deny the application on that objective ground. But whether a carpool lane belongs on a freeway is a policy question, and it should be decided as one—not litigated through a fictionalized world of modeled projections about the lane’s “growth-inducing impacts,” untethered from measured conditions.

Fourth, return permit enforcement to a law-enforcement model and end the era of environmental lawfare. That lawfare is conducted by just a handful of opportunistic plaintiffs with a clear agenda. In a 2025 analysis of 387 appellate NEPA cases by the Breakthrough Institute and attorneys at Holland & Knight, environmental nonprofits appeared as plaintiffs in roughly three-quarters of court judgments, and just ten organizations accounted for 35 percent of all cases. Only about a quarter of rulings found any legal flaw in the agency’s review.

The point of these suits is not to force a few more months of study or another modest condition, but to block the project or others like it. Some environmental organizations sue to thwart wind, solar, and transmission projects. Others sue to block oil, gas, manufacturing, or roads. Still others fight vegetation management meant to prevent catastrophic wildfire. Individuals and local groups sue to stop whatever is new and preserve whatever is old.

Whether an agency has complied with NEPA or permit law is a law-enforcement question, and suits to block projects on that basis should be reserved to the U.S. or state attorneys general. Individuals who allege individual harm from a project would retain their due-process rights, but the judicial remedy would be an order requiring the agency to address the harm, through compensation, relocation, or project modification—not by voiding the approval. Rescinding an approved project would be the rare exception, available only where no lesser remedy cures an unlawful harm.

Fifth, provide mandatory tracking of outcomes. Every permitting agency should be required to publish a dashboard showing, for each project, the initial application date, the date the application was deemed complete, the date of final action, whether post-approval litigation is pending, when construction began, and when it finished. Nothing more is needed—not how many notices went out or how many community meetings were held. Where an applicant supplies estimated capital costs at each stage, the agency should publish those on the same dashboard.

Agencies that fail to act on applications in a timely way should be required, within 12 months, to amend their own regulations to speed things up. Congress has imposed a version of this discipline on the IRS, which must track the most litigated tax issues and recommend clarifications or amendments to reduce future challenges.

None of these proposals weakens a single environmental standard. Rather, each rebuilds the legal infrastructure of permitting around qualities the current system doesn’t deliver: objectivity, transparency, and accountability.

The abundance agenda now rests on a bipartisan acceptance that America needs to build—and quickly. But until Congress changes the legal framework that makes permitting so slow, each NEPA fix will only redirect the delay, not end it.

Donate

City Journal is a publication of the Manhattan Institute for Policy Research (MI), a leading free-market think tank. Are you interested in supporting the magazine? As a 501(c)(3) nonprofit, donations in support of MI and City Journal are fully tax-deductible as provided by law (EIN #13-2912529).



Read the whole story
bogorad
5 days ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete

Civil Terrorism Is a Threat to American Democracy

1 Share
  • Definition of civil terrorism: Political coercion can include not only bombings and assassinations but also speech suppression, intimidation, and efforts to disrupt institutions.
  • Targeting Representative Smith: The congressman reported home vandalism, a driveway fire, nighttime demonstrations, disrupted town halls, and a staff member’s assault.
  • Impact on policy: Smith acknowledged that these threats contributed to his vote to reduce American aid to Israel, demonstrating how intimidation can influence congressional decisions.
  • Democratic risk: Lawless pressure bypasses reasoned debate and lawful political channels, potentially making elected officials and other lawmakers more vulnerable to coercion.
  • Need for enforcement: Crimes intended to intimidate or coerce public officials should receive more serious treatment than comparable offenses lacking that political purpose.
  • State legislation: Utah has enacted felony penalties for civil-terrorism offenses, providing a model for other states and possible federal action.
  • Deterrence: Failure to punish intimidation, vandalism, arson, and violence can encourage further attacks and weaken public institutions.



In his opening remarks at last week’s State Department ministerial on “the resurgence of political terrorism,” Secretary of State Marco Rubio contrasted “overt” forms of left-wing terrorism such as “bombings, assassinations, and organized violence in our streets” with “quieter” forms, like efforts to “suppress speech, intimidate political opposition, and sabotage our national institutions.” But he identified both as terrorism: breaking laws to achieve political goals through coercion.

I’m glad that the Secretary of State is on board with the recognition that we should treat these “quieter” forms, which I call civil terrorism, as a serious threat to our national security and the integrity of our political institutions.

Nothing is exaggerated or overblown about this characterization of the threat. On the very day of Secretary Rubio’s remarks, Washington Representative Adam Smith, the ranking Democrat on the House Armed Services committee, put out a statement explaining why he had voted the day before to cut American aid to Israel. “My family and I have had our home vandalized, a fire has been set in my driveway, my neighbors’ lives have been disrupted by demonstrations in the middle of the night, town halls meant to be forums for dialogue have been shut down, and a staff member has been physically assaulted.”

This is a remarkable admission. A member of Congress has admitted that he cast an important vote—in a “very close” call—at least in part because he had been targeted by lawless anti-Israel fanatics. The vandals, arsonists, and demonstrators wanted Representative Smith to know that he could not feel secure until he gave up his long-running support for the Jewish state. They figured that he would eventually conclude that harboring views at odds with theirs—even if they remain views held by millions of Americans—was not worth the trouble, the threats, the danger. And they were right.

There are at least two scandals here. The first is that Smith capitulated to his tormentors. He claims to be “deeply concerned about the tactics used by those on the far left to advocate cutting off aid to Israel.” Yet he is not so concerned as to deter their future use. He should have dug in his heels and vowed that each act of civil terrorism would lead only to a swift action from law enforcement officers and more military credits for Israel. Civil terrorists are not trying to persuade you but to strongarm you. Once you show them that you can be coerced, you have only made yourself—and, in this case, other lawmakers—a likelier target for future intimidation.

The second scandal is that no institutions stepped up to eliminate this despicable threat to our democratic system before it began swaying congressional votes. Legislators can and must be persuaded by citizens—when those citizens make reasoned arguments and explain why their way is better than the alternative. Shameful as it is that Smith had to suffer threats and violence against his family, it is even worse that Americans are choosing to tolerate a systematic, lawless effort to circumvent the proper channels for political change. Civil terrorism is an assault on our democracy.

States, including Representative Smith’s Washington, must crack down on civil terrorism by increasing penalties for crimes committed with the intent to intimidate or coerce. Vandalizing anyone’s house is bad enough; vandalizing an elected official’s house to send a message about the costs of supporting a particular policy is much worse, yet authorities usually treat the latter as misdemeanors not worth prosecuting.

Utah recently passed a bill making acts of civil terrorism into felonies, ensuring that they will be deterred or met with severe punishment. Every state should follow suit, and the federal government should consider its own parallel actions.

Each act of civil terrorism that goes unpunished only emboldens the perpetrators further to disfigure our politics and sabotage our nation.

Donate

City Journal is a publication of the Manhattan Institute for Policy Research (MI), a leading free-market think tank. Are you interested in supporting the magazine? As a 501(c)(3) nonprofit, donations in support of MI and City Journal are fully tax-deductible as provided by law (EIN #13-2912529).



Read the whole story
bogorad
5 days ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete

China’s Top AI Event Delivers Message to the U.S.: We’re Coming for You - WSJ

1 Share

LLM (google/gemini-3.1-flash-lite) summary:

  • Event Logistics: crowded exhibition hall in shanghai featured poor ventilation and archaic cooling methods despite the supposed innovation on display.
  • Corporate Posturing: chinese firms rapidly cycled through announcements of new ai models to cultivate an appearance of competing with established western systems.
  • Hardware Reality: exhibit floors were saturated with repetitive robotic gimmicks that struggled to perform elementary tasks reliably during live demonstrations.
  • Sanction Impact: export controls on specialized chips forced artificial constraints on chinese premium subscription services due to depleted computing resources.
  • Strategic Mimicry: observers noted a historical pattern where firms copy western industrial development cycles to eventually assert market dominance through scale.
  • Intellectual Appropriation: accusations persist that chinese labs bypassed development hurdles by distilling and exploiting proprietary technologies leaked from american models.
  • State Mandates: centralized government policy directs the forced integration of ai automation across ninety percent of the national economy by the end of the decade.
  • Manufacturing Performance: chinese robotics companies emphasized supply chain integration, though current hardware remains prone to mechanical failure and clumsy physical execution.

By

Katrina Northrop

in Shanghai and

Raffaele Huang

in Singapore

People attend the World Artificial Intelligence Conference in Shanghai.Tens of thousands of people lined up for this year’s World Artificial Intelligence Conference. Go Nakamura/Reuters

Inside China’s biggest artificial-intelligence convention, visitors wilted under the heat. With all the hot air from computer servers, people resorted to the ancient device of paper fans and organizers placed large ice blocks all over the exhibition hall.

If the Shanghai event was uncomfortable for the public who lined up by the tens of thousands to get in, it was just as much so for American companies competing with Chinese AI technology. On the first day, Beijing-based Moonshot AI jolted global markets with a new model seen as ranking with the world’s best. It took just two days for another Chinese company, Alibaba 9988 3.73%increase; up pointing triangle, to claim to have topped Moonshot with its own new model.

Some 20 football fields of exhibition space were filled with hardware trying to apply AI to everyday life, such as earbuds that listen to a meeting and produce a transcript. Robots were everywhere, dancing in unison, making cappuccinos, shooting soccer goals, massaging visitors and playing the piano. A furry AI pet batted its eyelashes at cooing onlookers. 

This was the ninth year for the annual World Artificial Intelligence Conference in Shanghai, and it has emerged as the premier occasion for China to strut its stuff in AI. Beijing flaunted its prowess at overcoming U.S. sanctions that largely block Chinese companies’ access to the best AI chips and chip-making equipment.

“It’s fun to be at the frontier of the whole thing,” said an Alibaba business development manager at the company’s booth.

A humanoid robot in an Argentina football shirt prepares to kick a soccer ball, while people watch from behind a barrier.Humanoid robots at the event demonstrated some of the potential real-world applications of AI. Hector Retamal/AFP/Getty Images

Not everything worked right. The humanoids are still better at gimmicky tricks than useful household tasks. And in an indication of how U.S. export controls are biting, Moonshot had to halt new subscriptions for its premium services after demand for its Kimi K3 model strained its computing resources.  

Still, China’s advances dashed any hopes the U.S. held for building an impregnable lead in AI

Chinese AI models are gaining traction globally, including in the U.S., partly because many are open-source—allowing people to freely download and adapt them—and are generally cheaper to run than Western models. That mirrors the pattern of industries such as smartphones, electric vehicles and batteries, which emerged in the West only for China to seize dominant market share. 

“If it’s already happened in three industries, could that happen in AI as well? My answer would be, just given what’s already happening in AI today, it’s likely,” said Mehran Gul, an author and speaker on technology.

Anthropic and OpenAI have accused several Chinese companies of tapping American models to train their own, a practice that Anthropic called “adversarial distillation.” Last week, an Anthropic executive said the U.S. lead over Chinese companies could have been a year to 18 months if they hadn’t distilled American models.

Moonshot’s new Kimi K3 model has upended this discussion because it earned higher scores in many benchmarks than Anthropic’s Claude Opus 4.8, the most powerful model it could distill. Research has suggested that a smaller model rarely surpasses the bigger model it distills. In light of Kimi K3, some researchers including OpenAI executive Dean Ball said distillation no longer explained the rapid advances of Chinese models.

China is now focusing on AI adoption, with a government blueprint called AI Plus saying the technology should be used in 90% of the economy by 2030. That explains the proliferation at the Shanghai show of robots, AI gadgets and “agentic” products that can automate complex tasks such as schedule planning.

People walk past a L’Oreal booth displaying an AI-powered beauty advertisement at the World Artificial Intelligence Conference in Shanghai.A host of brands took up positions at the summit. Go Nakamura/Reuters

“Our main focus this year is to find real-world agentic use cases where AI models can be used by many people,” said Steven Hoi, an Alibaba executive.

China’s manufacturing skills give it an edge in deploying AI in the real world. 

“A robot is a complex system, there are many, many components,” said Wang Xiaogang, the chairman of Chinese firm Ace Robotics, in an interview at the conference. “You need not just a single company, you need a long supply chain and many partners. In China, they are very good at this.” 

At the booth for Suzhou-based UniX AI, a $44,000 robot completed household tasks, such as making the bed, putting laundry in the washing machine and doing the dishes. A marketing representative said the robot was already being used in hotels and restaurants.

“Even though it might not be 100% mature right now, once it truly matures and stabilizes, it’s quite possible it could perform even better than humans,” he said.

But dreaded chores aren’t history yet. In a demo, the robot was shaky and slow, with laundry getting stuck on its claw-like hands. Once it missed the dishwasher altogether, sending a plate clattering to the floor.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Appeared in the July 21, 2026, print edition as 'China’s AI Advances Put U.S. Tech Firms on Notice'.

Katrina Northrop is a reporter for The Wall Street Journal covering the Chinese economy from Singapore. Previously, she was a China correspondent for the Washington Post and a staff writer at The Wire China, where she covered China's global impact on business and technology.

Raffaele Huang is a reporter for The Wall Street Journal in Singapore, covering Asia’s technology companies. Previously, he mainly focused on corporate news in the automotive and technology sector in Beijing.


Up Next


Videos

Read the whole story
bogorad
5 days ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete

Trump Says ABC, NBC Should Lose Licenses Over Refusal To Carry Speech

1 Share

LLM (google/gemini-3.1-flash-lite) summary:

  • Broadcast Refusal: major television networks opted not to air a twenty five minute presidential speech on their primary channels
  • Hostile Rhetoric: accusations were leveled against media organizations alleging a coordinated fraudulent conspiracy and a lack of patriotic intent
  • License Threats: demands were made to revoke broadcast credentials due to perceived biases in coverage and reporting standards
  • Unverified Claims: assertions regarding widespread voter fraud and foreign access to registration data lacked provided evidence
  • Media Countermeasures: networks employed editorial fact checking and expert analysis to immediately challenge the validity of the statements provided
  • Regulatory Friction: government oversight bodies initiated investigations into network operations potentially linked to executive disputes
  • Partisan Dismissals: legislative figures characterized the security warnings as laughable distractions from public record realities
  • Legislative Deadlock: proposals for stricter voter registration requirements face significant procedural hurdles in the senate

UPDATED: Donald Trump lashed out at ABC and NBC, the two networks that chose not to carry his speech live on their broadcast platforms, as he delivered a 25-minute long speech full of claims that included China obtaining voter registration data and the “deep state” withholding that intelligence from him.

Without evidence, Trump claimed that ABC and NBC and others in the media were part of a “plot” and “want to continue this fraud for whatever reason. They want to keep it going. They want to protect the radical left. They can’t have a great country, and that’s true. You can’t have a great country without free and fair elections. Fraud like this should mean a revocation of their licenses. They use our public multi-billion dollar in value airwaves for absolutely no money. They pay nothing. All we want is honesty in our elections and honesty in reporting.”

The networks had announced earlier in the day that they would not carry the speech, but would feature it live on their streaming channels.

Watch on Deadline

CBS News did air the speech — albeit not in its entirety. But anchor Tony Dokoupil preceded the address by telling viewers, “Honestly, much of what the president has said on this topic is false.” He then explained why they were doing a special report, noting, “This speech will be made. It will be news. And it is our job to cover the news.”

Then he went to Major Garrett, who offered some context on what viewers could expect to hear. After CBS News cut away from the speech, Garrett noted that trump’s claim of non-citizens and dead people on the voter rolls was “unsubstantiated.”

Garrett said, “Tony, you have to ask yourself, what does that rhetoric about? Is that rhetoric about setting the stage for federal intervention in the midterms? I mean, we’ve had primary elections all this year. We’re going to have more in August. Those primary elections have been conducted under this system that the president said is catastrophically vulnerable. Yet he and all Republicans and Democrats have accepted the election.”

President Trump in his primetime address on election integrity claimed “hundreds of thousands of non-citizens and dead people are listed and active on the voter rolls.”

FACT CHECK RATING: Exaggerated.

While election experts indicate that votes cast on behalf of “dead people”… pic.twitter.com/x71dEAnJaB

— CBS News (@CBSNews) July 17, 2026

One of the most newsworthy claims — that China acquired 220 million voter records — was also addressed on the network by David Becker, of the Center for Election Innovation & Research. “It sounds bad when you hear about it, right? But the reality is, voter files in the United States are public.”

Trump’s threat of NBC and ABC is nothing new. he’s done that before. But ABC already has been ordered to put the licenses of its eight owned and operated stations up for an early renewal by the FCC and its chairman, Brendan Carr. Such a rare move opens up the stations to challenges to its licenses as the FCC determines whether they have served the “public interest.”

ABC is challenging the early license renewal, calling it an “extraordinary demonstration of power and coercion.” Carr has said that the early license renewal was tied to an investigation of the network’s diversity, equity and inclusion practices, but it was launched after Trump called on the network to fire Jimmy Kimmel.

The FCC also is investigating NBC-parent Comcast over DEI, but Carr has not said whether he would call for additional early license renewals.

Despite ABC and NBC not airing the speech, A spokesperson for Sinclair Broadcast Group said that its network affiliates preempted network programming to air the speech via its news service, The National News Desk.

In the aftermath of the speech, networks devoted some time to fact checking, while some commentators referred to the newly released intelligence with some skepticism.

Sen. Mark Warner (D-VA), the top Democrat on the Senate Intelligence Committee, posted on X, “It’s pretty laughable to watch Trump try and pretend accessing the voter file is the same thing as election interference. Any statewide candidate will tell you that information is publicly available to purchase — it’s not some huge breach.” On CBS News, he chided the network for carrying the speech, but Dokoupil noted that Warner was part of their effort to also provide extensive context, fact-checking and analysis.

On CNN, Ben Ginsberg, a longtime election law lawyer, said that “what stood out to me is that there still is no evidence of a result of any election being incorrect. There still were not the documents, there still was not the evidence, although we’ll see what is produced.” He noted that the administration has cut back on cybersecurity agencies that could assist states on addressing security vulnerabilities.

Trump used the speech to try to pressure Congress to pass the Save America Act, legislation that would require proof of citizenship, like a birth certificate or passport, to register to vote, and an ID to cast a ballot. The legislation, though, likely would need to overcome a 60-vote threshold to advance in the Senate, something that is unlikely unless the Republican majority attempts to eliminate the filibuster.

Broadcast networks have declined to carry speeches by Trump’s predecessors, including Joe Biden and Barack Obama.

Anna Gomez, the sole Democrat on the FCC, posted on X, “It is ridiculous to call for broadcasters to lose their license simply for making the same editorial decisions they’ve made under presidents of both parties. Those editorial decisions are protected by the First Amendment, and the FCC has no authority to punish a station for refusing to air a blatantly political speech. This is a naked attempt to bully broadcasters, and the FCC should have no part in it.”

Read the whole story
bogorad
6 days ago
reply
Barcelona, Catalonia, Spain
Share this story
Delete
Next Page of Stories